Source:http://linkedlifedata.com/resource/pubmed/id/19531101
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-8-20
|
| pubmed:abstractText |
Previous studies showed that human leukocyte antigen (HLA)-G is specifically upregulated in renal cell carcinoma (RCC). However, a larger cohort of RCC patients are necessary to obtain more information. In this study, 109 RCC primary lesions (clear cell, n = 95; chromophobe, n = 4; papillary, n = 4; collecting duct, n = 6) and corresponding adjacent tumor-negative renal tissues (n = 34) were analyzed for the HLA-G expression by immunohistochemistry (IHC). Meanwhile, plasma soluble HLA-G (sHLA-G) from 16 RCC patients and 144 sex- and age-matched normal individuals was detected by enzyme-linked immunosorbent assay. Correlations between lesion HLA-G expression and various clinical parameters were evaluated. Receiver-operating characteristic (ROC) curve analysis was used to determine the feasibility of HLA-G protein staining and sHLA-G as a diagnosis marker for RCC. IHC data showed that HLA-G was observed in 49.5% of clear cell, 50% of either chromophobe or collecting duct RCC lesions but undetectable in papillary RCC and tumor-negative renal tissues. This finding was consistent with the western blot results. sHLA-G was pronouncedly increased in RCC patients when compared with normal controls (median: 39.5 vs 19.2 U/ml, P = 0.002). However, no correlation was observed between HLA-G expression and various clinical parameters. We found that the area under ROC curve for HLA-G expression and sHLA-G was 0.739 [95% confidence interval (95% CI): 0.659-0.816, P = 0.000] and 0.733 (95% CI: 0.619-0.847, P = 0.002), respectively. Our findings indicated that, except the papillary RCC, other types of RCC could express HLA-G. Furthermore, both lesion HLA-G expression and plasma sHLA-G level might be a useful preoperative biomarker for diagnosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-G Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1399-0039
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
74
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
213-21
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:19531101-Age Distribution,
pubmed-meshheading:19531101-Carcinoma, Renal Cell,
pubmed-meshheading:19531101-Case-Control Studies,
pubmed-meshheading:19531101-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:19531101-Feasibility Studies,
pubmed-meshheading:19531101-Female,
pubmed-meshheading:19531101-Gene Expression,
pubmed-meshheading:19531101-HLA Antigens,
pubmed-meshheading:19531101-HLA-G Antigens,
pubmed-meshheading:19531101-Histocompatibility Antigens Class I,
pubmed-meshheading:19531101-Histocompatibility Antigens Class II,
pubmed-meshheading:19531101-Humans,
pubmed-meshheading:19531101-Immunohistochemistry,
pubmed-meshheading:19531101-Kidney Neoplasms,
pubmed-meshheading:19531101-Male,
pubmed-meshheading:19531101-Middle Aged,
pubmed-meshheading:19531101-ROC Curve,
pubmed-meshheading:19531101-Solubility,
pubmed-meshheading:19531101-Tumor Markers, Biological
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Characterization of HLA-G expression in renal cell carcinoma.
|
| pubmed:affiliation |
Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Linhai, Zhejiang, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|